These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9628841)

  • 21. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
    Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
    Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early antiretroviral therapy: rationale, protease inhibitor-sparing regimens and once daily dosing.
    Gatell JM
    Antivir Ther; 1998; 3 Suppl 4():49-53. PubMed ID: 10723510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children.
    Lambert JS; Machado ES; Watson DC; Sill AM; Lim JK; Charurat M; Cunha SM; Afonso AO; Oliviera RH; Tanuri A; DeVico AL
    Pediatr Infect Dis J; 2007 Oct; 26(10):935-44. PubMed ID: 17901800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Explicitly accounting for antiretroviral drug uptake in theoretical HIV models predicts long-term failure of protease-only therapy.
    Smith RJ
    J Theor Biol; 2008 Mar; 251(2):227-37. PubMed ID: 18191950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Jones LE; Perelson AS
    Bull Math Biol; 2005 Nov; 67(6):1227-51. PubMed ID: 16023709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
    Nowak MA; Bonhoeffer S; Shaw GM; May RM
    J Theor Biol; 1997 Jan; 184(2):203-17. PubMed ID: 9059598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Target cell limited and immune control models of HIV infection: a comparison.
    De Boer RJ; Perelson AS
    J Theor Biol; 1998 Feb; 190(3):201-14. PubMed ID: 9514649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals.
    Cohen OJ; Pantaleo G; Schwartzentruber DJ; Graziosi C; Vaccarezza M; Fauci AS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S6-14. PubMed ID: 8595512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid screening of antiretroviral combinations.
    St Clair M; Pennington KN; Rooney J; Barry DW
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S24-7. PubMed ID: 8595504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance, remission, and qualitative differences in HIV chemotherapy.
    Kirschner DE; Webb GF
    Emerg Infect Dis; 1997; 3(3):273-83. PubMed ID: 9284371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of latently infected cells on strain archiving within HIV hosts.
    Ward Z; White J
    Bull Math Biol; 2012 Sep; 74(9):1985-2003. PubMed ID: 22777711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the impact of target cell heterogeneity on HIV loads in a within-host model.
    Ward ZD; White KA; van Voorn GA
    Epidemics; 2009 Sep; 1(3):168-74. PubMed ID: 21352764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to protease inhibitors in a model of HIV-1 infection with impulsive drug effects.
    Miron RE; Smith RJ
    Bull Math Biol; 2014 Jan; 76(1):59-97. PubMed ID: 24194434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV viral dynamics.
    Coffin JM
    AIDS; 1996 Dec; 10 Suppl 3():S75-84. PubMed ID: 8970715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding drug resistance for monotherapy treatment of HIV infection.
    Kirschner DE; Webb GF
    Bull Math Biol; 1997 Jul; 59(4):763-85. PubMed ID: 9214852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiretroviral therapy in infants and children with HIV.
    Wood GE
    Pediatr Nurs; 1995; 21(3):291-6. PubMed ID: 7792112
    [No Abstract]   [Full Text] [Related]  

  • 39. Dynamics of HIV infection of CD4+ T cells.
    Perelson AS; Kirschner DE; De Boer R
    Math Biosci; 1993 Mar; 114(1):81-125. PubMed ID: 8096155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mathematical model for HIV dynamics with multiple infections: implications for immune escape.
    Deng Q; Guo T; Qiu Z; Chen Y
    J Math Biol; 2024 May; 89(1):6. PubMed ID: 38762831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.